主要用于医药领域相关研究（基于参考文献中多次出现的医药化学研究背景）
医药
合成路线 1（1. 合成：80360-20-9）
产率：97%
合成条件：Stage #1: With sodium hydride In tetrahydrofuran; mineral oil at 20℃; Cooling with ice Stage #2: at 20℃;
实验步骤：将NaH（60％在矿物油中的分散体，40.00mmol，0.96g）分批加入搅拌的吲哚-3-甲醛11（20.00mmol，2.90g）在无水THF（50mL）中的溶液中，在冰浴中冷却，然后缓慢 允许温暖到rt 搅拌30分钟后，滴加PhSO 2 Cl（24.00mmol，4.24g）的无水THF溶液。 当TLC监测显示原料11已消失时，将反应混合物减压蒸发除去溶剂，然后用冰水（300mL）稀释。 滤出固体产物，用丙酮/石油醚（60-90℃）重结晶，得到所需中间体12，产率97％，熔点151-153℃.1H NMR（600MHz，CDCl3）：δ：7.37（ t，J = 7.2Hz，1H），7.42（dd，J = 11.4,4.2Hz，1H），7.52（t，J = 7.8Hz，2H），7.62（t，J = 7.2Hz，1H），7.97（ t，J = 7.8Hz，3H），8.20-8.31（m，2H），10.11（s，1H）。 HRMS（MALDI）：m / z 286.0515。计算。 C 15 H 11 NO 3 S：286.0538 [M + H] +。
参考文献：
- [1] Synlett, 1999, # 6, p. 786 - 788 [2] European Journal of Medicinal Chemistry, 2012, vol. 53, p. 283 - 291 [3] Journal of Organic Chemistry, 2002, vol. 67, # 3, p. 1001 - 1003 [4] Synthetic Communications, 2007, vol. 37, # 5, p. 829 - 837 [5] Tetrahedron, 1998, vol. 54, # 46, p. 13915 - 13928 [6] Journal of Organic Chemistry, 2005, vol. 70, # 15, p. 5840 - 5851 [7] Synthetic Communications, 1996, vol. 26, # 8, p. 1525 - 1538 [8] Heterocycles, 2011, vol. 82, # 2, p. 1617 - 1631 [9] Tetrahedron, 1999, vol. 55, # 19, p. 6243 - 6260 [10] Journal of the American Chemical Society, 1988, vol. 110, p. 7188 [11] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 11, p. 2469 - 2473 [12] Journal of Organic Chemistry, 2011, vol. 76, # 6, p. 1554 - 1561 [13] Chemical and pharmaceutical bulletin, 1987, vol. 35, # 6, p. 2261 - 2265 [14] Tetrahedron Letters, 1983, vol. 24, # 49, p. 5435 - 5438 [15] Tetrahedron, 1999, vol. 55, # 33, p. 10135 - 10154 [16] Synlett, 1997, vol. 1997, # 3, p. 289 - 290 [17] Tetrahedron, 1998, vol. 54, # 14, p. 3549 - 3566 [18] European Journal of Medicinal Chemistry, 2010, vol. 45, # 11, p. 5428 - 5437 [19] Chemical Biology and Drug Design, 2014, vol. 83, # 2, p. 224 - 236 [20] Tetrahedron Letters, 2010, vol. 51, # 2, p. 238 - 239 [21] Chemical and Pharmaceutical Bulletin, 2009, vol. 57, # 5, p. 536 - 540 [22] Patent: WO2011/109059, 2011, A1. Location in patent: Paragraph 0045; 00391 [23] Journal of Medicinal Chemistry, 2012, vol. 55, # 16, p. 7285 - 7289,5 [24] Journal of Medicinal Chemistry, 2012, vol. 55, # 16, p. 7285 - 7289 [25] Patent: WO2014/138279, 2014, A1. Location in patent: Paragraph 00247 [26] Journal of Organic Chemistry, 1984, vol. 49, # 23, p. 4518 - 4523 [27] Journal of Organic Chemistry, 1992, vol. 57, # 22, p. 5878 - 5891 [28] Chemistry of Heterocyclic Compounds, 2000, vol. 36, # 10, p. 1141 - 1148 [29] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 8, p. 2342 - 2346 [30] Journal of Medicinal Chemistry, 2007, vol. 50, # 18, p. 4548 - 4552 [31] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 24, p. 7274 - 7277 [32] Organic Letters, 2013, vol. 15, # 15, p. 3910 - 3913 [33] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 9, p. 993 - 997 [34] Patent: WO2016/14797, 2016, A1. Location in patent: Page/Page column 39 [35] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 18, p. 4403 - 4407 [36] Synthetic Communications, 2016, vol. 46, # 23, p. 1902 - 1908 [37] Journal of Medicinal Chemistry, 2017, vol. 60, # 5, p. 1843 - 1859 [38] Molecules, 2017, vol. 22, # 6, [39] Organic and Biomolecular Chemistry, 2017, vol. 15, # 35, p. 7404 - 7410 [40] Patent: CN107522650, 2017, A. Location in patent: Paragraph 0021 [41] Patent: WO2004/48330, 2004, A1. Location in patent: Page 44
